Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

BACKGROUND: Nivolumab plus ipilimumab (N‐I) or pembrolizumab (PEM) is associated with survival improvement as chemotherapy‐free, first‐line treatment for patients with advanced non‐small cell lung carcinoma (NSCLC) and positive programmed cell death ligand 1 (PD‐L1). However, no direct comparison da...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Transl Med
Main Authors: Zhou, Yixin, Zhang, Yaqiong, Guo, Guifang, Cai, Xiuyu, Yu, Hui, Cai, Yanyu, Zhang, Bei, Hong, Shaodong, Zhang, Li
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Research Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7240850/
https://ncbi.nlm.nih.gov/pubmed/32508007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.14
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker